These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 25046550)
1. Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program. Berrocal A; Arance A; Lopez Martin JA; Soriano V; Muñoz E; Alonso L; Espinosa E; Lopez Criado P; Valdivia J; Martin Algarra S; Melanoma Res; 2014 Dec; 24(6):577-83. PubMed ID: 25046550 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Altomonte M; Di Giacomo A; Queirolo P; Ascierto P; Spagnolo F; Bajetta E; Calabrò L; Danielli R; de Rosa F; Maur M; Chiarion-Sileni V; Ferrucci P; Giannarelli D; Testori A; Ridolfi R; Maio M J Exp Clin Cancer Res; 2013 Oct; 32(1):82. PubMed ID: 24423086 [TBL] [Abstract][Full Text] [Related]
3. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Ahmad SS; Qian W; Ellis S; Mason E; Khattak MA; Gupta A; Shaw H; Quinton A; Kovarikova J; Thillai K; Rao A; Board R; Nobes J; Dalgleish A; Grumett S; Maraveyas A; Danson S; Talbot T; Harries M; Marples M; Plummer R; Kumar S; Nathan P; Middleton MR; Larkin J; Lorigan P; Wheater M; Ottensmeier CH; Corrie PG Melanoma Res; 2015 Oct; 25(5):432-42. PubMed ID: 26225580 [TBL] [Abstract][Full Text] [Related]
4. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434 [TBL] [Abstract][Full Text] [Related]
5. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900 [TBL] [Abstract][Full Text] [Related]
7. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Delyon J; Mateus C; Lefeuvre D; Lanoy E; Zitvogel L; Chaput N; Roy S; Eggermont AM; Routier E; Robert C Ann Oncol; 2013 Jun; 24(6):1697-703. PubMed ID: 23439861 [TBL] [Abstract][Full Text] [Related]
8. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719 [TBL] [Abstract][Full Text] [Related]
10. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718 [TBL] [Abstract][Full Text] [Related]
11. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591 [TBL] [Abstract][Full Text] [Related]
12. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208 [TBL] [Abstract][Full Text] [Related]
13. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Alexander M; Mellor JD; McArthur G; Kee D Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899 [TBL] [Abstract][Full Text] [Related]
14. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295 [TBL] [Abstract][Full Text] [Related]
15. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085 [TBL] [Abstract][Full Text] [Related]
16. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164 [TBL] [Abstract][Full Text] [Related]
17. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319 [TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Johnson DB; Peng C; Abramson RG; Ye F; Zhao S; Wolchok JD; Sosman JA; Carvajal RD; Ariyan CE Oncologist; 2015 Jun; 20(6):648-52. PubMed ID: 25964307 [TBL] [Abstract][Full Text] [Related]
19. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488 [TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Kelderman S; Heemskerk B; van Tinteren H; van den Brom RR; Hospers GA; van den Eertwegh AJ; Kapiteijn EW; de Groot JW; Soetekouw P; Jansen RL; Fiets E; Furness AJ; Renn A; Krzystanek M; Szallasi Z; Lorigan P; Gore ME; Schumacher TN; Haanen JB; Larkin JM; Blank CU Cancer Immunol Immunother; 2014 May; 63(5):449-58. PubMed ID: 24609989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]